Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA.

Palladini G, Kastritis E, Maurer MS, Zonder JA, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics TJ, Rosenzweig MA, Sanchorawala V, Qin X, Vasey SY, Weiss B, Vermeulen J, Merlini G, Comenzo RL.

Blood. 2020 Apr 3. pii: blood.2019004460. doi: 10.1182/blood.2019004460. [Epub ahead of print]

PMID:
32244252
2.

Amyloidosis Diagnosed in Solid Organ Transplant Recipients.

Sharpley FA, Fontana M, Gilbertson JA, Gillmore JD, Hawkins PN, Mahmood S, Manwani R, Martinez-Naharro A, Quarta C, Rezk TM, Rowczenio D, Sachchithanantham S, Whelan CJ, Wechalekar AD, Lachmann HJ.

Transplantation. 2020 Feb;104(2):415-420. doi: 10.1097/TP.0000000000002813.

PMID:
32004234
3.

Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis.

Cohen OC, Sharpley F, Gillmore JD, Lachmann HJ, Sachchithanantham S, Mahmood S, Fontana M, Whelan CJ, Martinez-Naharro A, Kyriakou C, Rabin N, Popat R, Yong K, Cheesman S, Shah R, Hawkins PN, Wechalekar AD.

Br J Haematol. 2020 Jan 26. doi: 10.1111/bjh.16401. [Epub ahead of print]

PMID:
31984481
4.

Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis.

Chacko L, Martone R, Bandera F, Lane T, Martinez-Naharro A, Boldrini M, Rezk T, Whelan C, Quarta C, Rowczenio D, Gilbertson JA, Wongwarawipat T, Lachmann H, Wechalekar A, Sachchithanantham S, Mahmood S, Marcucci R, Knight D, Hutt D, Moon J, Petrie A, Cappelli F, Guazzi M, Hawkins PN, Gillmore JD, Fontana M.

Eur Heart J. 2020 Apr 7;41(14):1439-1447. doi: 10.1093/eurheartj/ehz905.

PMID:
31950987
5.

Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis.

Sharpley FA, De-Silva D, Mahmood S, Sachchithanantham S, Ramsay I, Garcia Mingo A, Worthington S, Hughes D, Mehta A, Kyriakou C, Griffiths PD, Wechalekar AD.

Eur J Haematol. 2020 Mar;104(3):230-235. doi: 10.1111/ejh.13366. Epub 2020 Jan 10.

PMID:
31815313
6.

Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance.

Chattopadhyay S, Thomsen H, Weinhold N, Meziane I, Huhn S, da Silva Filho MI, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Schmidt B, Landi S, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Houlston R, Goldschmidt H, Hemminki K, Försti A.

Leukemia. 2020 Apr;34(4):1187-1191. doi: 10.1038/s41375-019-0619-1. Epub 2019 Nov 6. No abstract available.

PMID:
31695157
7.

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.

Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, Lachmann HJ, Quarta C, Fontana M, Gillmore JD, Whelan C, Hawkins PN, Wechalekar AD.

Blood. 2019 Dec 19;134(25):2271-2280. doi: 10.1182/blood.2019000834.

PMID:
31578202
8.

A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom.

Sharpley FA, Petrie A, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Fontana M, Martinez-Naharro A, Quarta C, Hawkins PN, Wechalekar AD.

Br J Haematol. 2019 Dec;187(5):642-652. doi: 10.1111/bjh.16143. Epub 2019 Aug 13.

PMID:
31410841
9.

Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.

Sharpley FA, Fontana M, Martinez-Naharro A, Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Hawkins PN, Wechalekar AD.

Haematologica. 2019 Aug 8. pii: haematol.2019.217695. doi: 10.3324/haematol.2019.217695. [Epub ahead of print]

10.

Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.

Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Yong K, Rabin N, Popat R, Kyriakou C, Worthington S, Sharpley F, Smith M, Shah R, Cheesman S, Hawkins PN, Wechalekar AD.

Br J Haematol. 2019 Dec;187(5):638-641. doi: 10.1111/bjh.16122. Epub 2019 Aug 6.

PMID:
31388995
11.

Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis.

Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, Gritti M, Quarta C, Knight DS, Wechalekar AD, Lachmann HJ, Perlini S, Pontone G, Moon JC, Kellman P, Gillmore JD, Hawkins PN, Fontana M.

JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 1):69-80. doi: 10.1016/j.jcmg.2019.03.026. Epub 2019 Jun 12.

PMID:
31202744
12.

Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.

Rezk T, Lachmann HJ, Fontana M, Naharro AM, Sachchithanantham S, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Hawkins PN, Gillmore JD.

Br J Haematol. 2019 Aug;186(3):460-470. doi: 10.1111/bjh.15955. Epub 2019 May 24.

PMID:
31124579
13.

Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.

Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD.

Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21. Erratum in: Circulation. 2019 Jul 30;140(5):e185.

PMID:
31109193
14.

Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3.

Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G.

Toxicol Rep. 2019 Apr 19;6:369-379. doi: 10.1016/j.toxrep.2019.04.006. eCollection 2019.

15.

Spinal Stenosis in Familial Transthyretin Amyloidosis.

Carr AS, Shah S, Choi D, Blake J, Phadke R, Gilbertson J, Whelan CJ, Wechalekar AD, Gillmore JD, Hawkins PN, Reilly MM.

J Neuromuscul Dis. 2019;6(2):267-270. doi: 10.3233/JND-180348.

PMID:
30856118
16.

The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis.

Rezk T, Gilbertson JA, Mangione PP, Rowczenio D, Rendell NB, Canetti D, Lachmann HJ, Wechalekar AD, Bass P, Hawkins PN, Bellotti V, Taylor GW, Gillmore JD.

J Pathol Clin Res. 2019 Jul;5(3):145-153. doi: 10.1002/cjp2.126. Epub 2019 Apr 2.

17.

A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis.

Sharpley FA, Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Fontana M, Hawkins PN, Wechalekar AD.

Blood Cancer J. 2019 Feb 4;9(2):16. doi: 10.1038/s41408-019-0180-1. No abstract available.

18.

A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement.

Manwani R, Page J, Lane T, Burniston M, Skillen A, Lachmann HJ, Gillmore JD, Fontana M, Whelan C, Hawkins PN, Wagner T, Wechalekar AD.

Amyloid. 2018 Dec;25(4):247-252. doi: 10.1080/13506129.2018.1552852. Epub 2019 Jan 19.

PMID:
30661419
19.

Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres.

Chan EHL, De-Silva D, Lin AHF, Rabin N, Wechalekar A, Popat R, Chng WJ, Yong KL.

Br J Haematol. 2019 Jul;186(1):162-165. doi: 10.1111/bjh.15743. Epub 2018 Dec 28. No abstract available.

PMID:
30592025
20.

Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0102-7.

PMID:
30568288
21.

The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH.

Nat Rev Nephrol. 2019 Jan;15(1):45-59. doi: 10.1038/s41581-018-0077-4. Erratum in: Nat Rev Nephrol. 2019 Feb;15(2):121.

22.

Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis.

Ross JC, Hutt DF, Burniston M, Page J, Steeden JA, Gillmore JD, Wechalekar AD, Hawkins PN, Fontana M.

Amyloid. 2018 Sep;25(3):203-210. doi: 10.1080/13506129.2018.1520087.

PMID:
30486686
23.

Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis.

Rezk T, Davenport A, Gan JJ, Lachmann HJ, Fontana M, Martinez-Naharro A, Sachchithanantham S, Guillotte C, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Hawkins PN, Gillmore JD.

Br J Haematol. 2019 Jun;185(5):977-980. doi: 10.1111/bjh.15675. Epub 2018 Nov 18. No abstract available.

PMID:
30450572
24.

The genomic landscape of plasma cells in systemic light chain amyloidosis.

Boyle EM, Ashby C, Wardell CP, Rowczenio D, Sachchithanantham S, Wang Y, Johnson SK, Bauer MA, Weinhold N, Kaiser MF, Johnson DC, Jones JR, Pawlyn C, Proszek P, Schinke C, Facon T, Dumontet C, Davies FE, Morgan GJ, Walker BA, Wechalekar AD.

Blood. 2018 Dec 27;132(26):2775-2777. doi: 10.1182/blood-2018-08-872226. Epub 2018 Nov 16. No abstract available.

PMID:
30446495
25.

Deferred autologous stem cell transplantation in systemic AL amyloidosis.

Manwani R, Hegenbart U, Mahmood S, Sachchithanantham S, Kyriakou C, Yong K, Popat R, Rabin N, Whelan C, Dittrich T, Kimmich C, Hawkins P, Schönland S, Wechalekar A.

Blood Cancer J. 2018 Nov 5;8(11):101. doi: 10.1038/s41408-018-0137-9.

26.

Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience.

Rowczenio D, Quarta CC, Fontana M, Whelan CJ, Martinez-Naharro A, Trojer H, Baginska A, Ferguson SM, Gilbertson J, Rezk T, Sachchithanantham S, Mahmood S, Manwani R, Sharpley F, Wechalekar AD, Hawkins PN, Gillmore JD, Lachmann HJ.

Hum Mutat. 2019 Jan;40(1):90-96. doi: 10.1002/humu.23669. Epub 2018 Nov 1.

PMID:
30328212
27.

Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.

Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G.

Br J Haematol. 2019 May;185(3):588-592. doi: 10.1111/bjh.15569. Epub 2018 Sep 26. No abstract available.

28.

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.

Wong SW, Hegenbart U, Palladini G, Shah GL, Landau HJ, Warner M, Toskic D, Jaccard A, Hansen T, Bladé J, Cibeira MT, Kastritis E, Dispenzieri A, Wechalekar A, Varga C, Schönland SO, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e493-e499. doi: 10.1016/j.clml.2018.07.292. Epub 2018 Jul 25.

29.

Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis.

Sharpley FA, Manwani R, Mahmood S, Sachchithanantham S, Lachmann H, Gilmore J, Whelan C, Hawkins P, Wechalekar A.

Br J Haematol. 2018 Nov;183(4):557-563. doi: 10.1111/bjh.15541. Epub 2018 Aug 10.

PMID:
30095161
30.

Myocardial Edema and Prognosis in Amyloidosis.

Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, Knight DS, Zumbo G, Rosmini S, Maestrini V, Bulluck H, Rakhit RD, Wechalekar AD, Gilbertson J, Sheppard MN, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

J Am Coll Cardiol. 2018 Jun 26;71(25):2919-2931. doi: 10.1016/j.jacc.2018.03.536.

31.

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.

Manwani R, Sachchithanantham S, Mahmood S, Foard D, Sharpley F, Rezk T, Lane T, Quarta C, Fontana M, Lachmann HJ, Gillmore JD, Whelan C, Hawkins PN, Wechalekar AD.

Blood. 2018 Aug 16;132(7):761-764. doi: 10.1182/blood-2018-04-846493. Epub 2018 Jun 20. No abstract available.

PMID:
29925500
32.

Successful treatment of systemic AA amyloidosis associated with underlying Hodgkin lymphoma.

Manwani R, Wrench D, Wechalekar A, Lachmann H.

Br J Haematol. 2018 Sep;182(5):619. doi: 10.1111/bjh.15269. Epub 2018 May 16. No abstract available.

PMID:
29767440
33.

Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.

Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Kotecha T, Francis R, Rezk T, Quarta CC, Whelan CJ, Lachmann HJ, Wechalekar AD, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

JACC Cardiovasc Imaging. 2019 May;12(5):823-833. doi: 10.1016/j.jcmg.2018.02.016. Epub 2018 Apr 18.

PMID:
29680336
34.

Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds.

Wagner T, Page J, Burniston M, Skillen A, Ross JC, Manwani R, McCool D, Hawkins PN, Wechalekar AD.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1129-1138. doi: 10.1007/s00259-018-3995-2. Epub 2018 Apr 12.

35.

[18F]Florbetaben PET-CT confirms AL amyloidosis in a patient with Waldenström's Macroglobulinemia.

Fox TA, Lunn M, Wechalekar A, Bomanji J, Wan S, D'Sa S.

Haematologica. 2018 Jul;103(7):e322-e324. doi: 10.3324/haematol.2017.184515. Epub 2018 Apr 12. No abstract available.

36.

Biomarkers in AL amyloidosis: is the summit in sight?

Wechalekar AD.

Blood. 2018 Apr 5;131(14):1502-1503. doi: 10.1182/blood-2018-02-832113. No abstract available.

PMID:
29622535
37.

Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis.

Rezk T, Gilbertson JA, Rowczenio D, Bass P, Lachmann HJ, Wechalekar AD, Fontana M, Mahmood S, Sachchithanantham S, Whelan CJ, Wong J, Rendell N, Taylor GW, Hawkins PN, Gillmore JD.

Nephrol Dial Transplant. 2018 Feb 1;33(2):241-247. doi: 10.1093/ndt/gfw375.

PMID:
29401357
38.

Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis.

Manwani R, Foard D, Mahmood S, Sachchithanantham S, Lane T, Quarta C, Youngstein T, Rezk T, Lachmann HJ, Gillmore JD, Fontana M, Whelan C, Hawkins PN, Wechalekar A.

Haematologica. 2018 Apr;103(4):e165-e168. doi: 10.3324/haematol.2017.178095. Epub 2018 Jan 5. No abstract available.

39.

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.

Richards DB, Cookson LM, Barton SV, Liefaard L, Lane T, Hutt DF, Ritter JM, Fontana M, Moon JC, Gillmore JD, Wechalekar A, Hawkins PN, Pepys MB.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaan3128. doi: 10.1126/scitranslmed.aan3128.

PMID:
29298867
40.

Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome.

Rowczenio DM, Pathak S, Arostegui JI, Mensa-Vilaro A, Omoyinmi E, Brogan P, Lipsker D, Scambler T, Owen R, Trojer H, Baginska A, Gillmore JD, Wechalekar AD, Lane T, Williams R, Youngstein T, Hawkins PN, Savic S, Lachmann HJ.

Blood. 2018 Mar 1;131(9):974-981. doi: 10.1182/blood-2017-10-810366. Epub 2017 Dec 28.

41.

Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein.

Rowczenio D, Stensland M, de Souza GA, Strøm EH, Gilbertson JA, Taylor G, Rendell N, Minogue S, Efebera YA, Lachmann HJ, Wechalekar AD, Hawkins PN, Heimdal KR, Selvig K, Lægreid IK, Demoulin N, Aydin S, Gillmore JD, Wien TN.

Kidney Int Rep. 2016 Nov 19;2(3):461-469. doi: 10.1016/j.ekir.2016.11.005. eCollection 2017 May.

42.

Role of 99m Tc-DPD scintigraphy in imaging extra-cardiac light chain (AL) amyloidosis.

Sachchithanantham S, Hutt DF, Quigley AM, Hawkins P, Wechalekar AD.

Br J Haematol. 2018 Nov;183(3):506-509. doi: 10.1111/bjh.14988. Epub 2017 Oct 30. No abstract available.

PMID:
29082513
43.

Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.

Sachchithanantham S, Berlanga O, Alvi A, Mahmood SA, Lachmann HJ, Gillmore JD, Hawkins PN, Harding S, Wechalekar AD.

Br J Haematol. 2017 Nov;179(4):575-585. doi: 10.1111/bjh.14908. Epub 2017 Oct 8.

PMID:
28990174
44.

Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study.

Phillips EH, Nash S, Adedayo T, Whelan CJ, Fontana M, Mahmood S, Lachmann HJ, Gillmore JD, Smith P, Clifton-Hadley L, Hawkins PN, Wechalekar AD.

Amyloid. 2017 Dec;24(4):242-244. doi: 10.1080/13506129.2017.1385453. Epub 2017 Oct 6. No abstract available.

PMID:
28984490
45.

Challenging Occam's Razor: An Unusual Combination of Sarcoidosis and Amyloidosis. The Value of Cardiac Magnetic Resonance Imaging in Infiltrative Cardiomyopathies.

Nyktari E, Vassiliou VS, Arzanauskaite M, Gatehouse P, Greiser A, Wechalekar A, Gilbertson J, Pierce I, Sharma R, Mohiaddin R.

Can J Cardiol. 2017 Oct;33(10):1335.e9-1335.e11. doi: 10.1016/j.cjca.2017.07.004. Epub 2017 Jul 18.

PMID:
28870471
46.

Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services.

Popat R, Dowling E, Achhala S, Pandit D, Rabin N, Kyriakou C, Mackinnon S, Yong K, Wechalekar A.

Br J Haematol. 2018 Sep;182(6):936-939. doi: 10.1111/bjh.14897. Epub 2017 Aug 18. No abstract available.

PMID:
28832959
47.

Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology.

Lane T, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ.

Amyloid. 2017 Sep;24(3):189-193. doi: 10.1080/13506129.2017.1352503. Epub 2017 Jul 26.

PMID:
28745926
48.

Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.

Rezk T, Lachmann HJ, Fontana M, Sachchithanantham S, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Bass P, Hawkins PN, Gillmore JD.

Kidney Int. 2017 Dec;92(6):1476-1483. doi: 10.1016/j.kint.2017.05.004. Epub 2017 Jul 18.

PMID:
28729034
49.

Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre.

Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood S, Sachchithanantham S, Fontana M, Youngstein T, Quarta CC, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ.

Amyloid. 2017 Sep;24(3):162-166. doi: 10.1080/13506129.2017.1342235. Epub 2017 Jul 7.

PMID:
28686088
50.

Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.

Meziane I, Huhn S, Filho MIDS, Weinhold N, Campo C, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Jauch A, Morgan GJ, Houlston R, Goldschmidt H, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Försti A, Schönland SO, Hemminki K.

Haematologica. 2017 Oct;102(10):e411-e414. doi: 10.3324/haematol.2017.171108. Epub 2017 Jul 4. No abstract available.

Supplemental Content

Loading ...
Support Center